Zeng N
Institute of Hepatology, Tongji Medical University, Wuhan.
Zhonghua Yi Xue Za Zhi. 1992 Mar;72(3):141-3, 189.
The plasma levels of platelet activating factor (PAF) were measured in 27 decompensated cirrhotic patients and 11 controls, using platelet aggregation bioassay. At the same time, the levels of endotoxin were also measured. The results showed that the levels of plasma PAF in decompensated cirrhotic patients were higher than those in the controls (5.34 +/- 1.94 ng/ml:1.18 +/- 0.24 ng/ml, P less than 0.01), and were higher in the cirrhotic patients with endotoxemia than in those without endotoxemia (6.19 +/- 2.21 ng/ml:3.89 +/- 0.92 ng/ml, P less than 0.01). The level of plasma PAF is related significantly to the level of endotoxin (r = 0.67, P less than 0.01)). We conclude that plasma PAF is increased in cirrhotic patients, especially in those with endotoxemia, and PAF could be involved in the pathophysiological changes in endotoxemia and other complications of cirrhosis.
采用血小板聚集生物测定法,对27例失代偿期肝硬化患者和11例对照者的血浆血小板活化因子(PAF)水平进行了检测。同时,也测定了内毒素水平。结果显示,失代偿期肝硬化患者的血浆PAF水平高于对照组(5.34±1.94 ng/ml比1.18±0.24 ng/ml,P<0.01),且伴有内毒素血症的肝硬化患者高于无内毒素血症者(6.19±2.21 ng/ml比3.89±0.92 ng/ml,P<0.01)。血浆PAF水平与内毒素水平显著相关(r=0.67,P<0.01)。我们得出结论,肝硬化患者血浆PAF升高,尤其是伴有内毒素血症者,PAF可能参与了内毒素血症及肝硬化其他并发症的病理生理变化。